Rilematovir

Generic Name: Rilematovir

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₀ClF_₃N_₄O_₃S

CAS Number: 1383450-81-4

Unique Ingredient Identifier: NQ99E8OH3P

Background: Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals

DelveInsight's 'Respiratory Syncytial Virus Pipeline Insight, 2024' report details 50+ companies developing 50+ therapies, including Nirsevimab, Sisunatovir, and RSVpreF, across various stages of clinical trials. Key companies include GSK, Pfizer, and Sanofi, with recent successes like GSK's Arexvy vaccine and MSD's clesrovimab. The report covers mechanism of action, route of administration, and market dynamics.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy